Table 1.

Deposition following administration of one single dose of four puffs of the beclomethasone/formoterol hydrofluoroalkane (100/6 μg) radiolabelled formulation in healthy subjects, asthmatic, and chronic obstructive pulmonary disease patients

	Healthy subjects (n=8)	Asthma patients (n=8)	COPD patients (n=8)
Lung deposition (percentage nominal dose)	34.08±9.30 (20.00-43.80)	30.86±8.89 (21.50-47.40)	33.10±8.90 (14.00-43.60)
C/P	1.42±0.32 (1.14-2.09)	1.96±0.43* (1.44-2.78)	1.94±0.69 (1.15-3.07)

*P=0.046 versus healthy subjects. C/P: Central/peripheral